Ionis and AstraZeneca Hit by Phase 3 Trial Failure for Eplontersen

Key Facts

In a development highlighting the high risks of biotech innovation, Ionis Pharmaceuticals and AstraZeneca announced that their Phase 3 CARDIO-TTRansform trial for eplontersen failed to meet its primary efficacy endpoint. The trial did not demonstrate a statistically significant reduction in the composite outcome of cardiovascular mortality and recurrent clinical events compared to a placebo through Week 140. This failure represents a major setback for the drug's development as a treatment for ATTR-CM, a progressive and fatal heart disease.

This clinical disappointment occurs amid a competitive landscape dominated by Pfizer’s Vyndaqel, which remains a standard of care in the ATTR-CM market. Per market data, AstraZeneca (AZN) shares closed at $189.28 on July 8, 2026. Industry experts note that the failure of eplontersen to differentiate itself in a contemporary patient population may lead to downward revisions of long-term revenue forecasts for Ionis, which has heavily marketed its RNA-targeted platform to investors.

Traders are closely watching Ionis (IONS) price action after the stock closed at $86.33 on July 7, 2026, with potential support levels being tested following the news. With no major pharmaceutical regulatory catalysts listed in the immediate seven-day calendar, market attention will shift to upcoming management commentary regarding the future of the eplontersen program and any potential impact on the broader partnership between the two firms.